Status:
UNKNOWN
Economic Evaluation of Innovative Molecular Analyses in Onco-haematology
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Collaborating Sponsors:
Ministry of Health, France
Conditions:
Haematological Malignancy
Eligibility:
All Genders
Brief Summary
To evaluate the impact of innovative molecular diagnostics on the clinical management of patients with haematological malignancies via updated Appropriate-Prescribing-Guides including Next-Generation ...
Detailed Description
The 12 somatic genetic cancer tests that have received temporary authorisation in France form the basis of this study. These tests are not yet in the national biology reimbursement nomenclature but ar...
Eligibility Criteria
Inclusion
- Patients with haematological malignancies referred for molecular diagnosis workup. RuBIH2 will focus on 5 clinical situations in onco-haematology:
- Myelodysplasia (MDS)
- Acute lymphocytic leukemia (T) (ALL)
- Lymphoproliferative disorders (LPD)
- Acute myeloblastic leukemia (AML)
- Myeloproliferative disorders (MPD)
Exclusion
- Other haematological diseases not included in the list above.
Key Trial Info
Start Date :
October 18 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2020
Estimated Enrollment :
3960 Patients enrolled
Trial Details
Trial ID
NCT03750994
Start Date
October 18 2018
End Date
October 1 2020
Last Update
November 23 2018
Active Locations (26)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre hospitalier régional universitaire de Lille
Lille, Hauts-de-France, France, 59000
2
CHU Angers
Angers, France
3
Hôpital Avicenne AP-HP
Bobigny, France
4
CHU de Bordeaux
Bordeaux, France